RAPPORT THERAPEUTICS INC

CEO’s 2,210‑share sale at $29.16 sparks debate—insider liquidity vs. confidence, amid rising insider buying and volatile stock price at Rapport Therapeutics.

Insider buys 3,600 Rapport shares, signaling confidence in its CNS pipeline amid market swings and a shift toward value‑based reimbursement. Discover the impact.

Insider buying at Rapport Therapeutics signals optimism amid a 10% drop; learn how a 0.3% stake could boost a 52‑week low stock.

Insightful analysis of CFO Ignelzi Troy A.’s recent 5,500‑share buy in Rapport Therapeutics and its impact on the company’s Phase‑2 success, cash runway, and future outlook.